Chemotherapy News and Research

Latest Chemotherapy News and Research

Drug shortages lead to rationing of critical medicines

Though a number of reasons have created the shortfalls, everyone agrees that the proliferation of "gray markets" is one of the biggest factors.

3 Oct 2011

Palmetto establishes formal coverage policy for all Medicare patients

Genomic Health, Inc. today announced that Palmetto GBA, the designated national contractor for its Oncotype DX colon cancer test, has established a formal coverage policy for all Medicare patients.

1 Oct 2011

Tomosynthesis offers women the next generation in breast cancer detection

Breast cancer is the second most common type of cancer among women in the United States, with approximately 200,000 new diagnoses each year. Early detection is key in the treatment of breast cancer and the biggest advancement for detection in 30 years has arrived at University Hospitals Case Medical Center - tomosynthesis, an innovative technology that provides three-dimensional detailed imaging of the breast.

1 Oct 2011

Combination therapy improves outcomes for liver cancer patients: Study

A combination of an oral drug, called sorafenib, and a method for injecting microbeads of chemotherapy directly into tumors has been proven safe for liver cancer patients and may improve outcomes for those who have these fast-growing, deadly tumors whose numbers are on the rise in the U.S.

1 Oct 2011

Less toxic amounts of chemotherapy medicine slows tumor growth: Scientists

University of Georgia scientists have found that smaller, less toxic amounts of chemotherapy medicine given frequently to mice with human prostate cancer noticeably slowed tumor growth.

1 Oct 2011

UAB Comprehensive Cancer Center receives NCI grant to renew support for cancer research program

The University of Alabama at Birmingham Comprehensive Cancer Center has received a five-year, $27.5 million Cancer Center Support Grant from the National Cancer Institute to renew support for its cancer research program through 2016.

1 Oct 2011

Blueberry powder may control triple negative breast cancer

In several studies recently conducted at the Beckman Research Institute at the City of Hope, Duarte, CA researchers found that feeding blueberry powder to mice significantly reduced the growth and spread of triple negative breast cancer cells, a very aggressive form of cancer.

1 Oct 2011

The West Clinic forms new comprehensive breast center

The West Clinic, the Mid-South's premier cancer practice, is pleased to announce the formation of The West Clinic Comprehensive Breast Center, a multidisciplinary breast center, which will be the first center of its kind in the region.

1 Oct 2011

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian Technologies Limited is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate clinical studies of VGX-100.

1 Oct 2011

Galectin posts new corporate video on galectin-inhibiting therapeutics to treat fibrosis and cancer

Galectin Therapeutics Inc. today announced that it posted a new corporate presentation video to its website, www.galectintherapeutics.com, that highlights the Company's leadership position in developing galectin-inhibiting therapeutics to treat fibrosis and cancer.

30 Sep 2011

Immunotherapeutics for treatment of metastatic melanoma

A new cancer research program at Loyola University Chicago Stritch School of Medicine will develop therapies designed to turn patients' own immune systems into potent weapons against cancer.

30 Sep 2011

G-Zero receives NIAID's Phase II Small Business Innovation Research Grant

G-Zero Therapeutics, an RTP company started in 2008 based on technologies from the University of North Carolina at Chapel Hill, has been awarded a $3 million Phase II Small Business Innovation Research Grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

30 Sep 2011

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical studies of VGX-100. The first trial (Phase I) will involve the treatment of a variety of different cancer types in patients with late stage cancer.

29 Sep 2011

Plausible way to circumvent drug resistance in breast cancer cells

Breast cancer cells that mutate to resist drug treatment survive by establishing tiny pumps on their surface that reject the drugs as they penetrate the cell membrane - making the cancer insensitive to chemotherapy drugs even after repeated use.

29 Sep 2011

Cubist plans to move CB-183,315 into Phase 3 trial for treatment of CDAD

Cubist Pharmaceuticals, Inc. today announced it plans to move CB-183,315, being studied for the treatment of a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea, or CDAD, into late-stage trials.

29 Sep 2011

UCSF scientists identify how normal cells transform into brain tumors

Brain tumor specimens taken from neurosurgery cases at the University of California, San Francisco (UCSF) Medical Center has given scientists a new window on the transformation that occurs as healthy brain cells begin to form tumors.

29 Sep 2011

Prototype drug shows promise against chronic lymphocytic leukemia

Pre-clinical research has generated some very promising findings about a prototype drug for the treatment of chronic lymphocytic leukemia.

29 Sep 2011

Johns Hopkins researchers discover oxaliplatin-based nerve damage

Oxaliplatin, a platinum-based anticancer drug that's made enormous headway in recent years against colorectal cancer, appears to cause nerve damage that may be permanent and worsens even months after treatment ends.

29 Sep 2011

New research on public perceptions about cancer

New research on public perceptions about cancer reveals that 50-year-old ideas still hold sway while many current lifestyle messages are not getting through.

28 Sep 2011

Treatment of CMV infection can inhibit medullablastomas development

Researchers at Karolinska Institutet in Sweden have demonstrated for the first time that it is possible to inhibit the growth of brain tumours by treating the common Cytomegalovirus (CMV). The virus, which is found in a wide range of tumour types, offers a possible route towards controlling tumour growth and reducing the size of the tumour as a complement to conventional cytotoxin-based therapies.

28 Sep 2011